EE04579B1 - Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks - Google Patents
Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviksInfo
- Publication number
- EE04579B1 EE04579B1 EEP200000770A EEP200000770A EE04579B1 EE 04579 B1 EE04579 B1 EE 04579B1 EE P200000770 A EEP200000770 A EE P200000770A EE P200000770 A EEP200000770 A EE P200000770A EE 04579 B1 EE04579 B1 EE 04579B1
- Authority
- EE
- Estonia
- Prior art keywords
- arthropathies
- preparation
- treatment
- pharmaceutical composition
- protein transferase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98202258 | 1998-07-06 | ||
PCT/EP1999/004546 WO2000001386A1 (en) | 1998-07-06 | 1999-06-30 | Farnesyl protein transferase inhibitors for treating arthropathies |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000770A EE200000770A (et) | 2002-04-15 |
EE04579B1 true EE04579B1 (et) | 2006-02-15 |
Family
ID=8233891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000770A EE04579B1 (et) | 1998-07-06 | 1999-06-30 | Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks |
Country Status (34)
Country | Link |
---|---|
US (1) | US6451812B1 (xx) |
EP (1) | EP1094815B1 (xx) |
JP (1) | JP4491136B2 (xx) |
KR (1) | KR100674122B1 (xx) |
CN (1) | CN1170538C (xx) |
AP (1) | AP1597A (xx) |
AT (1) | ATE253914T1 (xx) |
AU (1) | AU762470B2 (xx) |
BG (1) | BG64939B1 (xx) |
BR (1) | BR9911869A (xx) |
CA (1) | CA2337800C (xx) |
CZ (1) | CZ302269B6 (xx) |
DE (1) | DE69912790T2 (xx) |
DK (1) | DK1094815T3 (xx) |
EA (1) | EA003510B1 (xx) |
EE (1) | EE04579B1 (xx) |
ES (1) | ES2212580T3 (xx) |
HK (1) | HK1034450A1 (xx) |
HR (1) | HRP20000904A2 (xx) |
HU (1) | HU229358B1 (xx) |
ID (1) | ID27199A (xx) |
IL (2) | IL140720A0 (xx) |
MY (1) | MY122189A (xx) |
NO (1) | NO318338B1 (xx) |
NZ (1) | NZ509647A (xx) |
PL (1) | PL193296B1 (xx) |
PT (1) | PT1094815E (xx) |
SI (1) | SI1094815T1 (xx) |
SK (1) | SK285231B6 (xx) |
TR (1) | TR200003882T2 (xx) |
TW (1) | TW557212B (xx) |
UA (1) | UA64797C2 (xx) |
WO (1) | WO2000001386A1 (xx) |
ZA (1) | ZA200100152B (xx) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200003882T2 (tr) | 1998-07-06 | 2001-06-21 | Janssen Pharmaceutica N.V. | Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri. |
ATE259365T1 (de) * | 1999-11-30 | 2004-02-15 | Pfizer Prod Inc | Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
AU2001293826A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
AU2001293829A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives |
AU2001293835A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
JP4974438B2 (ja) | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体 |
ATE434615T1 (de) | 2000-11-21 | 2009-07-15 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
DE60117847T2 (de) | 2000-12-27 | 2006-11-16 | Janssen Pharmaceutica N.V. | Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate |
ES2263684T3 (es) * | 2000-12-27 | 2006-12-16 | Janssen Pharmaceutica N.V. | Derivados de 4-heterociclil-quinolina y -quinazolina que inhiben la farnesil transferasa. |
US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
WO2003000266A1 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinolines and uses thereof |
US6706699B2 (en) * | 2001-06-21 | 2004-03-16 | Ariad Pharmaceuticals, Inc. | Quinolines and uses thereof |
US7408063B2 (en) | 2001-12-19 | 2008-08-05 | Janssen Pharmaceutica, N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
CA2478813C (en) | 2002-03-22 | 2011-10-18 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
AU2003229688B2 (en) | 2002-04-15 | 2009-07-30 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Gtpアーゼ阻害剤および使用方法 |
WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
PT1815247E (pt) | 2004-11-05 | 2013-04-23 | Janssen Pharmaceutica Nv | Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
AU2006227377B2 (en) | 2005-03-18 | 2013-01-31 | Medimmune, Llc | Framework-shuffling of antibodies |
KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
US7826982B2 (en) | 2005-07-29 | 2010-11-02 | Children's Hospital Medical Center | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE |
WO2007075923A2 (en) | 2005-12-23 | 2007-07-05 | Link Medicine Corporation | Treatment of synucleinopathies |
MX2009002151A (es) | 2006-08-28 | 2009-07-03 | Kirin Pharma Kk | Anticuerpos monoclonales humanos especificos para light humano antagonistas. |
EP2077859A4 (en) | 2007-03-30 | 2010-11-24 | Medimmune Llc | ANTIBODY FORMULATION |
DK2160386T3 (da) * | 2007-05-23 | 2012-08-27 | Allergan Inc | Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser |
US8232402B2 (en) | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
JP2012508768A (ja) | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
FR2967353B1 (fr) | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
WO2012103165A2 (en) | 2011-01-26 | 2012-08-02 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
SG11201502757QA (en) | 2012-10-09 | 2015-05-28 | Igenica Biotherapeutics Inc | Anti-c16orf54 antibodies and methods of use thereof |
PL2909192T3 (pl) * | 2012-10-16 | 2017-09-29 | Janssen Pharmaceutica Nv | Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T |
KR20150070348A (ko) * | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
CN105073729A (zh) * | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
US10100123B2 (en) | 2013-06-06 | 2018-10-16 | Pierre Fabre Medicament | Anti-C10orf54 antibodies and uses thereof |
KR20160054501A (ko) | 2013-08-26 | 2016-05-16 | 맵백스 테라퓨틱스, 인코포레이티드 | 시알릴-루이스 a에 대한 사람 항체 코드화 핵산 |
JP6377152B2 (ja) * | 2013-10-15 | 2018-08-22 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのフェニル結合キノリニルモジュレータ |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9403816B2 (en) * | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9221804B2 (en) * | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
WO2015057629A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | ALKYL LINKED QUINOLINYL MODULATORS OF RORyt |
WO2015057626A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | QUINOLINYL MODULATORS OF RORyT |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9284308B2 (en) * | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015187811A2 (en) | 2014-06-04 | 2015-12-10 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside gd2 |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
ES2834739T3 (es) | 2014-12-11 | 2021-06-18 | Pf Medicament | Anticuerpos anti-C10orf54 y utilizaciones de los mismos |
PL3265123T3 (pl) | 2015-03-03 | 2023-03-13 | Kymab Limited | Przeciwciała, zastosowania i sposoby |
DK3277842T5 (da) | 2015-08-17 | 2020-08-31 | Kura Oncology Inc | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer |
CN114470194A (zh) | 2015-12-02 | 2022-05-13 | 斯特库伯株式会社 | 与btn1a1免疫特异性结合的抗体和分子及其治疗用途 |
CN108925136B (zh) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
KR20190082247A (ko) | 2016-11-03 | 2019-07-09 | 쿠라 온콜로지, 인크. | 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
AU2018277838A1 (en) | 2017-05-31 | 2019-12-19 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof |
US20200131266A1 (en) | 2017-05-31 | 2020-04-30 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー., インコーポレイテッド | Btn1a1又はbtn1a1リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN) |
MX2021000786A (es) | 2018-07-20 | 2021-06-15 | Pf Medicament | Receptor para supresor de ig del dominio v de activación de células t (vista). |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602184A (en) | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
US5574025A (en) * | 1994-10-26 | 1996-11-12 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
US5831004A (en) * | 1994-10-27 | 1998-11-03 | Affymax Technologies N.V. | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use |
FR2729390A1 (fr) * | 1995-01-18 | 1996-07-19 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
ES2175137T3 (es) * | 1995-12-08 | 2002-11-16 | Janssen Pharmaceutica Nv | Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa. |
WO1997038697A1 (en) | 1996-04-15 | 1997-10-23 | The Trustees Of The University Of Pennsylvania | Sensitization of cells to radiation and chemotherapy |
CA2260216A1 (en) * | 1996-07-15 | 1998-01-22 | Bristol-Myers Squibb Company | Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase |
TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
GB2323783A (en) * | 1997-04-02 | 1998-10-07 | Ferring Bv Group Holdings | Inhibitors of farnesyl protein transferase |
DE69838025T2 (de) | 1997-04-25 | 2008-05-08 | Janssen Pharmaceutica N.V. | Chinazolinone die farnesyltransferase hemmen |
DE69807222T2 (de) | 1997-06-02 | 2003-04-17 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen |
SK283820B6 (sk) | 1997-06-17 | 2004-02-03 | Schering Corporation | Tricyklická amidová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie |
TR200003882T2 (tr) | 1998-07-06 | 2001-06-21 | Janssen Pharmaceutica N.V. | Artropatilerin tedavisi için farnesil protein transferaz inhibitörleri. |
EA003877B1 (ru) | 1998-07-06 | 2003-10-30 | Янссен Фармацевтика Н.В. | Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами |
OA11645A (en) * | 1998-08-27 | 2004-11-16 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents. |
JP5574025B1 (ja) * | 2013-06-25 | 2014-08-20 | 大日本印刷株式会社 | 飲料供給系配管の殺菌方法及び装置 |
-
1999
- 1999-06-30 TR TR2000/03882T patent/TR200003882T2/xx unknown
- 1999-06-30 WO PCT/EP1999/004546 patent/WO2000001386A1/en not_active Application Discontinuation
- 1999-06-30 NZ NZ509647A patent/NZ509647A/en not_active IP Right Cessation
- 1999-06-30 US US09/743,077 patent/US6451812B1/en not_active Expired - Lifetime
- 1999-06-30 EA EA200100112A patent/EA003510B1/ru not_active IP Right Cessation
- 1999-06-30 EP EP99931230A patent/EP1094815B1/en not_active Expired - Lifetime
- 1999-06-30 UA UA2000127574A patent/UA64797C2/uk unknown
- 1999-06-30 ID IDW20010018A patent/ID27199A/id unknown
- 1999-06-30 PL PL345352A patent/PL193296B1/pl unknown
- 1999-06-30 AU AU47806/99A patent/AU762470B2/en not_active Expired
- 1999-06-30 AT AT99931230T patent/ATE253914T1/de active
- 1999-06-30 KR KR1020007014067A patent/KR100674122B1/ko not_active IP Right Cessation
- 1999-06-30 BR BR9911869-6A patent/BR9911869A/pt not_active Application Discontinuation
- 1999-06-30 SI SI9930475T patent/SI1094815T1/xx unknown
- 1999-06-30 CZ CZ20004778A patent/CZ302269B6/cs not_active IP Right Cessation
- 1999-06-30 DK DK99931230T patent/DK1094815T3/da active
- 1999-06-30 CN CNB998083119A patent/CN1170538C/zh not_active Expired - Lifetime
- 1999-06-30 DE DE69912790T patent/DE69912790T2/de not_active Expired - Lifetime
- 1999-06-30 HU HU0103670A patent/HU229358B1/hu unknown
- 1999-06-30 PT PT99931230T patent/PT1094815E/pt unknown
- 1999-06-30 AP APAP/P/2001/002058A patent/AP1597A/en active
- 1999-06-30 ES ES99931230T patent/ES2212580T3/es not_active Expired - Lifetime
- 1999-06-30 EE EEP200000770A patent/EE04579B1/xx unknown
- 1999-06-30 CA CA002337800A patent/CA2337800C/en not_active Expired - Lifetime
- 1999-06-30 JP JP2000557832A patent/JP4491136B2/ja not_active Expired - Lifetime
- 1999-06-30 SK SK1987-2000A patent/SK285231B6/sk not_active IP Right Cessation
- 1999-06-30 IL IL14072099A patent/IL140720A0/xx active IP Right Grant
- 1999-07-01 MY MYPI99002787A patent/MY122189A/en unknown
- 1999-07-05 TW TW088111347A patent/TW557212B/zh not_active IP Right Cessation
-
2000
- 2000-12-28 HR HR20000904A patent/HRP20000904A2/hr not_active Application Discontinuation
-
2001
- 2001-01-03 BG BG105110A patent/BG64939B1/bg unknown
- 2001-01-04 NO NO20010053A patent/NO318338B1/no not_active IP Right Cessation
- 2001-01-04 IL IL140720A patent/IL140720A/en not_active IP Right Cessation
- 2001-01-05 ZA ZA200100152A patent/ZA200100152B/en unknown
- 2001-07-18 HK HK01105022A patent/HK1034450A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200000770A (et) | Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks | |
EE200000794A (et) | Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis | |
DK1204410T3 (da) | Farmaceutisk doseringsform med flere komponenter | |
ATE258928T1 (de) | Respiratorisches syncytialvirus replikation inhibitoren | |
ATE259796T1 (de) | Respiratorisches syncytialvirus replikation inhibitoren | |
DE60038698D1 (de) | Hydrogel-gesteuerte dosierungsform | |
DE69928777D1 (de) | Dosierspender | |
NO20003219L (no) | Oral farmasøytisk doseringsform med pulsert frigivningsvirkning | |
NO20003218L (no) | Oral farmasøytisk doseringsform med forlenget frigivningsvirkning | |
NO20053106D0 (no) | Oral, analgesisk doseringsform med forlenget frigivelse. | |
NL300328I2 (nl) | Samenstelling orale dosering met verlengde afgifte | |
NO20021329D0 (no) | Kinaseinhibitorer som terapeutiske midler | |
DK1600154T3 (da) | Osmotisk doseringsform med forlænget frigivelse | |
DE69704965D1 (de) | Dosierungs-Ausgabebehälter | |
NO20010556L (no) | Fremgangsmate for oftalmisk administrering | |
HUP0203054A3 (en) | Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use | |
NO20012976D0 (no) | Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament | |
NO20002526D0 (no) | Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav | |
NO20002439D0 (no) | Nye orale doseringsformer for carvediol | |
HUP0102159A3 (en) | Pharmaceutical composition for the treatment of rumen acidosis | |
EE9400296A (et) | Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid | |
ID30032A (id) | Formulasi farmasi | |
DE10081194D2 (de) | Darreichungsform zur Applikation in Körperöffnungen | |
EE200100281A (et) | Analgeetiline ravimkoostis | |
IS5906A (is) | Sertralín efnisthykkni til gjafar um munn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |